Caroline Baumal Sells 2,816 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the transaction, the insider now directly owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Apellis Pharmaceuticals Stock Down 4.7 %

Shares of APLS stock opened at $33.00 on Thursday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock has a market cap of $4.10 billion, a PE ratio of -16.26 and a beta of 0.94. The business’s fifty day moving average is $31.66 and its 200-day moving average is $33.83. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter last year, the firm posted ($1.17) earnings per share. Apellis Pharmaceuticals’s revenue was up 78.3% compared to the same quarter last year. Equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Citigroup lowered their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target on the stock. Wells Fargo & Company reduced their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $25.00 target price on shares of Apellis Pharmaceuticals in a research report on Monday, November 4th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.94.

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. lifted its position in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after acquiring an additional 39,931 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after purchasing an additional 735,160 shares during the period. Profund Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 90.7% in the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after purchasing an additional 20,435 shares during the period. Algert Global LLC boosted its position in shares of Apellis Pharmaceuticals by 137.8% in the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after purchasing an additional 71,650 shares during the period. Finally, Edgestream Partners L.P. raised its holdings in Apellis Pharmaceuticals by 240.4% during the 2nd quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock worth $2,093,000 after buying an additional 38,541 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).